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Systemic fungal infections are increasing in number through- 
out the developed world. Two separate autopsy studies in 
Europe showed that 4% of patients dymg in teaching hospitals 
suffered from invasive aspergdlosis. Candidemia is the fourth 
most common hospital-acquired bloodbome pathogen in the 
USA. In a long-term national survey of causes of death in 
Japan, systemic fungal infections were found in 1.5-2% of 
patients, with an increasing incidence of disseminated infec- 
tions in the 1990s. Many studies, particularly those in Japan, 
show an increasing frequency of invasive aspergdlosis in 
patients not thought to be at risk, including those in intensive 
care, those with chronic chest disease, those treated with 
corticosteroids for autoimmune disease, among others. 
However, some hngal infections appear to be occurring less 
frequently than before. Pneumocystis can’nii pneumonia is now 
much less frequent in patients who are known to have HIV 
infection, and typically presents in those without knowledge of 
their HIV status. The use of growth factors following 
autologous stem-cell transplantation significantly reduced the 
period of neutropenia and the incidence of fungal infection to 
< 1%. Antifungal prophylaxis in neutropenic patients probably 
reduces the incidence of fungal infection by about 50%. The 
extensive use of fluconazole in intensive care units may have 
reduced the frequency of candidemia and other manifestations 
of candida infection, although this has not been shown in 
high-quahty epidemiological studies. 
Fungal infections expected to increase over the coming 
years include invasive aspergillosis in multiple patient groups, 
especially those at risk for long periods of time, such as 
allogeneic stem-cell transplant recipients. Cryptococcal me- 
ningitis and other fungal complications of HIV infection in the 
developing world will continue to be hghly prevalent and 
difficult to manage. The introduction of new antibiotics, such 
as the oxazilidones and another class of antibiotic will increase 
the risk of candida infections, similarly to all other antibiotics. 
More chronic indolent Aspergillus and other mould infections 
are likely to affect patients with chronic pulmonary problems. 
The introduction of ‘mini transplants’ may increase the risk of 
@-us.-host disease, with the consequence of significant 
fungal disease. 
In thls supplement, several prominent figures in the world 
of infectious &seam and medical mycology present reviews of 
the state of the art in current topics in fungal disease. Many key 
issues related to the prevention and management of serious 
fungal infections described above are summarized. 
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